Lung Cancer Genomic Testing Market Overview
The Lung Cancer Genomic Testing Market is expanding as genomic profiling becomes increasingly important in lung cancer diagnosis, prognosis, treatment selection, and monitoring. According to WiseGuyReports, the global market was valued at approximately USD 5.3 billion in 2024 and is projected to reach USD 13.5 billion by 2035, representing a CAGR of approximately 9.9% from 2025 to 2035. The increasing prevalence of lung cancer, growing adoption of precision medicine, advances in next-generation sequencing (NGS), and increasing use of targeted therapies are key factors supporting market growth.
Market Drivers
Growing Prevalence of Lung Cancer
The increasing global burden of lung cancer is creating greater demand for genomic testing that can help characterize tumors and identify clinically relevant genetic alterations. Genomic information can support physicians in selecting appropriate targeted therapies and developing more individualized treatment strategies.
Increasing Adoption of Precision Medicine
Precision medicine is becoming increasingly important in oncology. Lung cancer genomic testing can identify specific molecular alterations associated with tumor development, helping clinicians select therapies based on an individual patient’s genetic and molecular profile. The increasing adoption of personalized treatment approaches is therefore a major market driver.
Advancements in Next-Generation Sequencing
Next-generation sequencing enables simultaneous analysis of multiple genes and genomic alterations. Its expanding use in oncology is supporting broader molecular profiling and improving the ability to identify actionable mutations. WiseGuyReports identifies NGS as a leading technology segment within the lung cancer genomic testing market.
Growing Adoption of Liquid Biopsy
Liquid biopsy is gaining attention because it can provide tumor-related genomic information through blood samples and is less invasive than conventional tissue biopsy. Its potential applications include early detection, treatment-response monitoring, and detection of disease recurrence. The liquid biopsy segment is expected to grow rapidly during the forecast period.
Increasing Demand for Targeted Therapies
The growing availability of targeted treatments for molecularly defined lung cancer is increasing the need for genomic testing. Identifying relevant genetic alterations can help determine whether a patient is likely to benefit from a specific targeted therapy, supporting the expansion of companion and predictive testing.
Market Challenges
High Cost of Genomic Testing
Advanced genomic testing can require sophisticated sequencing platforms, specialized laboratory infrastructure, bioinformatics capabilities, and trained personnel. These requirements can increase testing costs and restrict access in price-sensitive healthcare markets.
Limited Access to Advanced Testing
Access to comprehensive genomic testing remains uneven across regions. Differences in healthcare infrastructure, reimbursement policies, laboratory capabilities, and availability of trained specialists can limit adoption, particularly in developing markets.
Complex Data Interpretation
Comprehensive genomic tests can generate large volumes of molecular information. Interpreting variants and distinguishing clinically actionable alterations from findings of uncertain significance requires specialized expertise and advanced bioinformatics systems.
Reimbursement Challenges
The availability and level of reimbursement for genomic testing vary considerably between healthcare systems. Uncertainty regarding coverage can affect physician adoption and patient access to advanced molecular diagnostics.
Regulatory and Data Privacy Requirements
Genomic information is highly sensitive, creating requirements related to data security, patient consent, privacy, laboratory quality, and regulatory compliance. Testing providers must maintain appropriate safeguards while ensuring analytical and clinical validity.
Browse In-depth Market Research Report on Lung Cancer Genomic Testing Market
Lung Cancer Genomic Testing Market Research Report
Market Segmentation
By Cancer Type
Non-Small Cell Lung Cancer (NSCLC): Represents the largest category of lung cancer and is a major application area for genomic profiling and targeted treatment selection.
Small Cell Lung Cancer (SCLC): Represents a smaller but clinically important segment where genomic research and molecular characterization continue to develop.
Other Lung Cancers: Includes less common lung malignancies requiring specialized molecular and genomic evaluation.
By Technology
Next-Generation Sequencing (NGS): Enables simultaneous analysis of multiple genes and is a major technology supporting comprehensive genomic profiling.
Polymerase Chain Reaction (PCR): Used to detect specific genetic mutations and remains an important molecular testing method.
Fluorescence In Situ Hybridization (FISH): Provides information about specific chromosomal abnormalities and gene alterations.
Comparative Genomic Hybridization (CGH): Used to identify genomic copy-number changes and other chromosomal alterations.
By Sample Type
Tissue Biopsy: Remains a widely used method for obtaining tumor material for genomic analysis and accounted for more than 60% of the market in 2023 according to WiseGuyReports.
Liquid Biopsy: Uses blood-based samples to detect circulating tumor DNA and other tumor-related biomarkers and is expected to experience rapid growth.
Other Samples: Includes additional biological materials used in specialized genomic testing applications.
By Target Type
Single-Gene Panels: Focus on individual genes associated with specific lung cancer mutations.
Multi-Gene Panels: Analyze multiple genes simultaneously and are increasingly important for comprehensive molecular profiling.
Whole Exome Sequencing (WES): Examines protein-coding regions across the genome to identify potentially relevant alterations.
Whole Genome Sequencing (WGS): Provides broad genomic analysis and can identify a wide range of genetic changes.
By Application
Diagnostic Testing: Helps identify molecular characteristics associated with lung cancer and supports disease classification.
Prognostic Testing: Provides genomic information that can contribute to assessment of disease progression and expected outcomes.
Predictive Testing: Helps identify genetic alterations that may indicate whether a patient is likely to respond to a particular therapy.
Treatment Response Monitoring: Enables molecular assessment during treatment to evaluate response and potentially identify emerging resistance or recurrence.
By Region
North America
Europe
Asia-Pacific
South America
Middle East & Africa
Regional Insights
North America
North America is the leading regional market for lung cancer genomic testing. WiseGuyReports estimates that the region accounted for approximately USD 2.2 billion in 2024 and is projected to reach USD 5.5 billion by 2035. Strong healthcare infrastructure, high adoption of precision medicine, substantial research investment, and the presence of major genomic testing companies are supporting regional dominance.
Europe
Europe represents a significant market supported by established healthcare systems, increasing adoption of precision oncology, research initiatives, and growing availability of genomic diagnostics. Continued investment in cancer research and molecular testing is expected to support market expansion.
Asia-Pacific
Asia-Pacific is expected to experience substantial growth as cancer incidence increases, healthcare infrastructure improves, and genomic testing becomes more accessible. WiseGuyReports projects the APAC market to reach approximately USD 2.5 billion by 2035, reflecting significant growth potential.
South America
South America is expected to experience moderate market development as healthcare systems increase their adoption of molecular diagnostics and precision oncology. Greater awareness of genomic testing and collaborations with international healthcare organizations may further support growth.
Middle East & Africa
The Middle East and Africa market is gradually developing as healthcare systems invest in advanced diagnostic technologies. Although limited access to specialized testing infrastructure remains a challenge, improvements in healthcare capacity and growing awareness of precision medicine should create opportunities.
Key Players
Key companies identified in the competitive landscape include:
Qiagen
Myriad Genetics
Roche
Guardant Health
Illumina
Thermo Fisher Scientific
Foundation Medicine
Caris Life Sciences
NeoGenomics Laboratories
Abbott Laboratories
Fulgent Genetics
Exact Sciences
Invitae
Genomic Health
PathAI
These companies are focusing on next-generation sequencing, liquid biopsy, molecular profiling, companion diagnostics, laboratory services, strategic collaborations, and expansion of precision-oncology testing capabilities. WiseGuyReports specifically identifies Qiagen, Myriad Genetics, Roche, and Guardant Health among notable players in the market.
Future Outlook
The Lung Cancer Genomic Testing Market is expected to experience strong growth through 2035 as genomic information becomes increasingly integrated into lung cancer diagnosis and treatment. WiseGuyReports projects the market to increase from USD 5.3 billion in 2024 to USD 13.5 billion by 2035, representing a CAGR of approximately 9.9% during 2025–2035.
Future opportunities are likely to center on next-generation sequencing, liquid biopsy, multi-gene panels, companion diagnostics, AI-assisted genomic interpretation, and treatment-response monitoring. Increasing use of molecularly targeted therapies should further strengthen demand for genomic testing. As precision oncology continues to evolve, genomic testing is expected to become an increasingly important component of personalized lung cancer management.
